Lexaria Bioscience (Lexaria Bioscience) Debt-to-EBITDA : -0.06 (As of Feb. 2024)

Lexaria Bioscience Debt-to-EBITDA Chart

Lexaria Bioscience Annual Data
	Trend	Oct13	Aug15	Aug16	Aug17	Aug18	Aug19	Aug20	Aug21	Aug22	Aug23
Debt-to-EBITDA		Get a 7-Day Free Trial					-	-0.04	-0.02	-0.01	-0.03

Lexaria Bioscience Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.01	-0.02	-0.04	-0.04	-0.06

Competitive Comparison of Lexaria Bioscience's Debt-to-EBITDA

For the Biotechnology subindustry, Lexaria Bioscience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexaria Bioscience's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Debt-to-EBITDA falls into.

Lexaria Bioscience Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lexaria Bioscience's Debt-to-EBITDA for the fiscal year that ended in Aug. 2023 is calculated as

Lexaria Bioscience's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Feb. 2024) EBITDA data.

Lexaria Bioscience  (NAS:LEXX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Lexaria Bioscience Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience (Lexaria Bioscience) Business Description